Positive results for ustekinumab in systemic lupus erythromatosus have been shown in a small Phase 2 trial of the anti-interleukin 12/23 antibody as add-on treatment. In a randomised controlled trial in 102 patients with active SLE, ustekinumab (Stelara) proved to be significantly better than placebo in improving clinical parameters of the disease. Published in the ...
High expectations for ustekinumab in SLE after positive Phase 2 trial
By Michael Woodhead
25 Sep 2018